IO Biotech (NASDAQ:IOBT – Get Free Report) is expected to announce its earnings results on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
IO Biotech Stock Performance
NASDAQ:IOBT opened at $1.05 on Tuesday. The stock has a market cap of $69.18 million, a price-to-earnings ratio of -0.77 and a beta of 0.24. IO Biotech has a 1 year low of $0.66 and a 1 year high of $1.85. The business has a fifty day moving average of $0.91 and a 200-day moving average of $1.03.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of IO Biotech in a research report on Tuesday, November 12th.
About IO Biotech
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Further Reading
- Five stocks we like better than IO Biotech
- Overbought Stocks Explained: Should You Trade Them?
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Which Wall Street Analysts are the Most Accurate?
- Price Targets on NVIDIA Rise in Front of Earnings
- How to Choose Top Rated Stocks
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
